Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,821,750
  • Shares Outstanding, K 122,492
  • Annual Sales, $ 196,540 K
  • Annual Income, $ -140,040 K
  • EBIT $ -38 M
  • EBITDA $ -43 M
  • 60-Month Beta 1.69
  • Price/Sales 19.42
  • Price/Cash Flow N/A
  • Price/Book 24.15

Options Overview Details

View History
  • Implied Volatility 58.95% (-11.11%)
  • Historical Volatility 82.21%
  • IV Percentile 6%
  • IV Rank 9.91%
  • IV High 116.97% on 08/01/25
  • IV Low 52.57% on 08/20/25
  • Expected Move (DTE 11) 2.17 (6.95%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 590
  • Volume Avg (30-Day) 879
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 17,984
  • Open Int (30-Day) 18,661
  • Expected Range 29.03 to 33.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.02
  • Number of Estimates 3
  • High Estimate 0.10
  • Low Estimate -0.05
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +122.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.26 +40.16%
on 11/14/25
31.45 -0.79%
on 12/05/25
+6.82 (+27.97%)
since 11/05/25
3-Month
16.57 +88.29%
on 09/25/25
31.45 -0.79%
on 12/05/25
+14.05 (+81.92%)
since 09/05/25
52-Week
11.13 +180.32%
on 02/11/25
31.45 -0.79%
on 12/05/25
+18.89 (+153.45%)
since 12/05/24

Most Recent Stories

More News
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children...

ARQT : 31.20 (+0.13%)
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA approved...

ARQT : 31.20 (+0.13%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 31.20 (+0.13%)
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved...

ARQT : 31.20 (+0.13%)
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin health ZORYVE® (roflumilast) is the #1 prescribed branded topical...

ARQT : 31.20 (+0.13%)
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can...

ARQT : 31.20 (+0.13%)
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

  Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025  ZORYVE cream 0.05% received U.S. Food...

ARQT : 31.20 (+0.13%)
Arcutis to Present at Upcoming Investor Conferences

WESTLAKE VILLAGE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 31.20 (+0.13%)
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged ≥2 years New long-term data demonstrate that ZORYVE cream was well-tolerated...

ARQT : 31.20 (+0.13%)
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Arcutis Biotherapeutics (ARQT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Senseonics Holdings (SENS – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report) with...

SENS : 6.62 (-1.63%)
ARQT : 31.20 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 32.70
2nd Resistance Point 32.08
1st Resistance Point 31.64
Last Price 31.20
1st Support Level 30.57
2nd Support Level 29.95
3rd Support Level 29.51

See More

52-Week High 31.45
Last Price 31.20
Fibonacci 61.8% 23.69
Fibonacci 50% 21.29
Fibonacci 38.2% 18.89
52-Week Low 11.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar